DOCSLIB.ORG

Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It molecules Review Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It Zeinab Breijyeh , Buthaina Jubeh and Rafik Karaman * Department of Bioorganic & Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Quds University, Jerusalem P.O. Box 20002, Palestine; [email protected] (Z.B.); [email protected] (B.J.) * Correspondence: [email protected] Received: 13 February 2020; Accepted: 12 March 2020; Published: 16 March 2020 Abstract: Antimicrobial resistance represents an enormous global health crisis and one of the most serious threats humans face today. Some bacterial strains have acquired resistance to nearly all antibiotics. Therefore, new antibacterial agents are crucially needed to overcome resistant bacteria. In 2017, the World Health Organization (WHO) has published a list of antibiotic-resistant priority pathogens, pathogens which present a great threat to humans and to which new antibiotics are urgently needed the list is categorized according to the urgency of need for new antibiotics as critical, high, and medium priority, in order to guide and promote research and development of new antibiotics. The majority of the WHO list is Gram-negative bacterial pathogens. Due to their distinctive structure, Gram-negative bacteria are more resistant than Gram-positive bacteria, and cause significant morbidity and mortality worldwide. Several strategies have been reported to fight and control resistant Gram-negative bacteria, like the development of antimicrobial auxiliary agents, structural modification of existing antibiotics, and research into and the study of chemical structures with new mechanisms of action and novel targets that resistant bacteria are sensitive to. Research efforts have been made to meet the urgent need for new treatments; some have succeeded to yield activity against resistant Gram-negative bacteria by deactivating the mechanism of resistance, like the action of the β-lactamase Inhibitor antibiotic adjuvants. Another promising trend was by referring to nature to develop naturally derived agents with antibacterial activity on novel targets, agents such as bacteriophages, DCAP(2-((3-(3,6-dichloro-9H-carbazol-9-yl)-2-hydroxypropyl)amino)-2(hydroxymethyl)propane1,3- diol, Odilorhabdins (ODLs), peptidic benzimidazoles, quorum sensing (QS) inhibitors, and metal-based antibacterial agents. Keywords: antimicrobial; antibiotic; resistance; Gram-negative; multidrug resistance (MDR); pathogens; bacteria; alternative therapies 1. Introduction Throughout history, natural products have been utilized to treat a variety of diseases; cinchona tree containing quinine to treat malaria, penicillin for the treatment of infectious diseases, and others. Since the discovery of penicillin by Fleming in 1929, a large number of antibacterial agents have been developed and have had a huge impact on human health and the mortality rates of humans around the world [1]. Widespread excessive dispensing and irresponsible use of antibiotics has resulted in the development of resistant strains. Unfortunately, most antibiotics are available over the counter in the developing countries and can be dispensed without prescription; therefore, patients and general public education are crucially needed [2]. Molecules 2020, 25, 1340; doi:10.3390/molecules25061340 www.mdpi.com/journal/molecules Molecules 2020, 25, 1340 2 of 23 MoleculesThe global 2020 e, ff25ort, x FOR to develop PEER REVIEW new antibiotics or modify existing ones to fight resistant pathogens2 of 25 globally is now huge. Antibiotic resistance evolves when the bacteria can escape the effect of antibioticscell, or modifying by diff erenttheir outer mechanisms, structure like resulting neutralizing in inhibition the antibiotics, of the drugs’ pumping attachment them to outside the bacteria. of the cell,The mechanisms or modifying of their antibiotic outer structureresistance resulting are categorized in inhibition into four of the groups: drugs’ intrinsic attachment resistance to the in bacteria. which Thebacteria mechanisms can change of antibiotic their structures resistance or are compon categorizedents, intoanother four groups:way is acquired intrinsic resistanceresistance, in where which bacteria cancan changeacquire their new structures resistance or components,genes and DN anotherA from way other is acquired resistant resistance, bacteria. whereFurthermore, bacteria cangenetic acquire changes new resistance in the DNA genes which and DNA can from alter other the resistantproduction bacteria. of protein Furthermore, leading genetic to different changes incomponents the DNA whichand receptors can alter that the productioncannot be ofrecognized protein leading by the to antibiotic, different componentsand finally DNA and receptors transfer thatthrough cannot a behorizontal recognized gene by thetransfer antibiotic, between and finally bacteria DNA via transfer transformation through a horizontalor transduction gene transfer or by betweenconjugation bacteria [3]. via transformation or transduction or by conjugation [3]. Resistance toto antimicrobialsantimicrobials isis aa growinggrowing crisis crisis in in clinical clinical medicine. medicine. In In 2017, 2017, the the WHO WHO published published a lista list of bacteriaof bacteria where where new new antibiotics antibiotics to tackle to tack themle arethem needed are urgentlyneeded urgently and grouped and themgrouped according them toaccording their priority to their as priority critical, high,as critical, and mediumhigh, and (Figure medium1). (Figure 1). Figure 1. WHO list of priority pathogens grouped under three priority categories according to Figure 1. WHO list of priority pathogens grouped under three priority categories according to their their antibiotic resistance: Critical, high and medium to encourage research and development of antibiotic resistance: Critical, high and medium to encourage research and development of new new antibiotics. antibiotics. Gram Negative Bacteria 1.1. Gram Negative Bacteria In 1884 Hans Christian Gram developed a method to distinguish between Gram-positive and Gram-negativeIn 1884 Hans bacteria Christian by using Gram a crystaldeveloped violet-iodine a method complex to distinguish and a safranin between counter Gram-positive stain. Gram- and positiveGram-negative bacteria bacteria stained by violet using or a purple crystal and violet-iodine Gram-negative complex bacteria and a don’tsafranin retain counter the complex stain. Gram- stain andpositive counter bacteria stain stained with safranin violet or to purple give a pinkand Gram-negative color. This diff erencebacteria is don’t due to retain the composition the complex or stain the morphologyand counter stain of the with cell wallsafranin in each to give bacterial a pink type color. [1, 2This]. difference is due to the composition or the morphology of the cell wall in each bacterial type [1,2]. Gram-negative bacteria have an envelope that consists of three layers (Figure 2).The first layer is the outer membrane (OM), a protective and a unique feature that distinguishes Gram-negative bacteria from Gram-positive bacteria. The OM has phospholipids that are bound to the inner leaflet Molecules 2020, 25, 1340 3 of 23 MoleculesGram-negative 2020, 25, x bacteria FOR PEER have REVIEW an envelope that consists of three layers (Figure2).The first layer3 of is25 the outer membrane (OM), a protective and a unique feature that distinguishes Gram-negative bacteria fromof the Gram-positive membrane, and bacteria. lipopolysaccharide The OM has (LPS) phospholipids bound to the that outer are boundleaflet towhich the inneris known leaflet to ofcause the membrane,endotoxic shock. and lipopolysaccharide Moreover, the OM (LPS) contains bound protei to thens outer called leaflet the outer which memb is knownrane to proteins cause endotoxic (OMPs) shock.such as Moreover,porins and the others OM which contains allow proteins the passage called theof small outer molecules membrane like proteins amino (OMPs)acids and such small as porinssaccharides. and others The whichsecond allow layer the is passagethe peptidoglyca of small moleculesn cell wall like which amino is acids a rigid and smallexoskeleton saccharides. that Thedetermines second the layer cell is shape the peptidoglycan and consists cellof a wallrepeat which unit isof a the rigid disaccharide exoskeleton N-acetyl that determines glucosamine-N- the cell shapeacetylmuramic and consists acid of [3]. a repeat The third unit oflayer the is disaccharide the inner membrane N-acetyl glucosamine-N-acetylmuramic (IM) which is a phospholipid acidbilayer [3]. Thethat thirdis responsible layer is thefor innermultifunctional membrane processes (IM) which likeis structure, a phospholipid transport, bilayer and biosynthetic that is responsible functions. for multifunctionalIn addition, it is processes the site likefor structure,DNA anchoring transport, and and plays biosynthetic an important functions. role Inin addition,sister chromosomes it is the site forseparation DNA anchoring [4]. and plays an important role in sister chromosomes separation [4]. Figure 2. A diagram describes the cell wall st structureructure of Gram-negative bacteria. The outer membrane of Gram-negative bacteria is the main reason for resistance to a wide range of antibiotics including ββ-lactams, quinilons, colistins and otherother antibiotics.antibiotics. Most antibiotics must pass thethe outerouter membranemembrane toto access access their their targets, targets, for for example, example, hydrophobic hydrophobic
Load more

Recommended publications
  • Mechanisms and Strategies to Overcome Multiple Drug Resistance in Cancer
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector FEBS Letters 580 (2006) 2903–2909 Minireview Mechanisms and strategies to overcome multiple drug resistance in cancer Tomris Ozben* Akdeniz University, Faculty of Medicine, Department of Biochemistry, 07070 Antalya, Turkey Received 30 January 2006; accepted 9 February 2006 Available online 17 February 2006 Edited by Horst Feldmann The cytotoxic drugs that are most frequently associated with Abstract One of the major problems in chemotherapy is multi- drug resistance (MDR) against anticancer drugs. ATP-binding MDR are hydrophobic, amphipathic natural products, such as cassette (ABC) transporters are a family of proteins that medi- the taxanes (paclitaxel and docetaxel), vinca alkaloids (vinorel- ate MDR via ATP-dependent drug efflux pumps. Many MDR bine, vincristine, and vinblastine), anthracyclines (doxorubicin, inhibitors have been identified, but none of them have been pro- daunorubicin, and epirubicin), epipodophyllotoxins (etoposide ven clinically useful without side effects. Efforts continue to dis- and teniposide), antimetabolites (methorexate, fluorouracil, cover not toxic MDR inhibitors which lack pharmacokinetic cytosar, 5-azacytosine, 6-mercaptopurine, and gemcitabine) interactions with anticancer drugs. Novel approaches have also topotecan, dactinomycin, and mitomycin C [4,6–8]. been designed to inhibit or circumvent MDR. In this review, Overexpression of ATP-binding cassette (ABC) transporters the structure and function of ABC transporters and development has been shown to be responsible for MDR [5]. Therefore eluci- of MDR inhibitors are described briefly including various ap- dation of the structure and function for each ABC transporter is proaches to suppress MDR mechanisms.
    [Show full text]
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • Surgical Decolonization and Prophylaxis
    Surgical Decolonization and Prophylaxis SurgicalSurgical Decolonization Decolonization and Prophylaxis and Prophylaxis DECOLONIZATION DECOLONIZATION Nasal Screening Result Recommended Intervention Nasal Screening Result Recommended Intervention MRSA Negative • No decolonization required MSSAMRSA NegativeNegative • No decolonization required MSSA PositiveNegative • Intranasal mupirocin twice daily x 5 days MSSA Positive • Intranasal mupirocin twice daily x 5 days MRSA Positive • Intranasal mupirocin twice daily x 5 days, MRSA Positive AND• Intranasal mupirocin twice daily x 5 days, •ANDChlorhexidine bathing one day prior to surgery ANTIMICROBIAL• ChlorhexidinePROPHYLAXISbathing one day prior to surgery ANTIMICROBIAL PROPHYLAXIS CLINICAL CONSIDERATIONS • Preoperative dose-timing CLINICAL CONSIDERATIONS • PreoperativeWithin 60 minutesdose-timing of surgical incision WithinExceptions: 60 minutes vancomycin of surgicaland fluoroquinolones incision within 120 minutes of surgical incisionExceptions: vancomycin and fluoroquinolones within 120 minutes of surgical • Weightincision-based dosing • WeightCefazolin-based: 2 gm dosingfor patients <120 kg, and 3 gm for patients ≥120 kg Vancomycin:Cefazolin: 2 gm usefor ABW patients <120 kg, and 3 gm for patients ≥120 kg Gentamicin:Vancomycin: use use ABW ABW unless ABW is >120% of their IBW, in which case use AdjBWGentamicin:(see below use ABW for equation)unless ABW is >120% of their IBW, in which case use • DurationAdjBW of(see prophylaxis below for equation) • DurationA single of dose, prophylaxis
    [Show full text]
  • Chapter 12 Antimicrobial Therapy Antibiotics
    Chapter 12 Antimicrobial Therapy Topics: • Ideal drug - Antimicrobial Therapy - Selective Toxicity • Terminology - Survey of Antimicrobial Drug • Antibiotics - Microbial Drug Resistance - Drug and Host Interaction An ideal antimicrobic: Chemotherapy is the use of any chemical - soluble in body fluids, agent in the treatment of disease. - selectively toxic , - nonallergenic, A chemotherapeutic agent or drug is any - reasonable half life (maintained at a chemical agent used in medical practice. constant therapeutic concentration) An antibiotic agent is usually considered to - unlikely to elicit resistance, be a chemical substance made by a - has a long shelf life, microorganism that can inhibit the growth or - reasonably priced. kill microorganisms. There is no ideal antimicrobic An antimicrobic or antimicrobial agent is Selective Toxicity - Drugs that specifically target a chemical substance similar to an microbial processes, and not the human host’s. antibiotic, but may be synthetic. Antibiotics Spectrum of antibiotics and targets • Naturally occurring antimicrobials – Metabolic products of bacteria and fungi – Reduce competition for nutrients and space • Bacteria – Streptomyces, Bacillus, • Molds – Penicillium, Cephalosporium * * 1 The mechanism of action for different 5 General Mechanisms of Action for antimicrobial drug targets in bacterial cells Antibiotics - Inhibition of Cell Wall Synthesis - Disruption of Cell Membrane Function - Inhibition of Protein Synthesis - Inhibition of Nucleic Acid Synthesis - Anti-metabolic activity Antibiotics
    [Show full text]
  • Electronic Supplementary Material (ESI) for Analyst. This Journal Is © the Royal Society of Chemistry 2017
    Electronic Supplementary Material (ESI) for Analyst. This journal is © The Royal Society of Chemistry 2017 Supplemental Table 2. Proteins Increased in Either Blood or Horizon media Table 2A. Proteins Increased in Spores Produced on Horizon Soil Over Spores Produced on Blood Medium quasi.fdr Protein Protein Class/Name KEGG Pathway Names or Function (if ID Pathways found in KEGG) Amino Acid Metabolism bat00250, bat00280, Alanine, aspartate and glutamate metabolism, bat00410, Valine, leucine and isoleucine degradation, bat00640, beta-Alanine metabolism to acetyl CoA, 4.50E-07 BAS0310 4-aminobutyrate aminotransferase bat00650 Propanoate metabolism, Butanoate metabolism bat00270, bat00330, Cysteine and methionine metabolism, Arginine bat00410, and proline metabolism, beta-Alanine 3.84E-10 BAS5060 spermidine synthase bat00480 metabolism, Glutathione metabolism bat00270, bat00330, Cysteine and methionine metabolism, Arginine bat00410, and proline metabolism, beta-Alanine 2.30E-09 BAS5219 spermidine synthase bat00480 metabolism, Glutathione metabolism bat00250, Alanine, aspartate and glutamate metabolism, 6.94E-07 BAS0561 alanine dehydrogenase bat00430 Taurine and hypotaurine metabolism bat00250, Alanine, aspartate and glutamate metabolism, 5.23E-07 BAS4521 alanine dehydrogenase bat00430 Taurine and hypotaurine metabolism 0.005627 BAS5218 agmatinase, putative bat00330 Arginine and proline metabolism 2,3,4,5-tetrahydropyridine-2- carboxylate N-succinyltransferase, 1.40E-10 BAS3891 putative bat00300 Lysine biosynthesis bat00010, bat00020, Glycolysis
    [Show full text]
  • Burkholderia Cepacia Complex As Human Pathogens1
    Journal of Nematology 35(2):212–217. 2003. © The Society of Nematologists 2003. Burkholderia cepacia Complex as Human Pathogens1 John J. LiPuma2 Abstract: Although sporadic human infection due to Burkholderia cepacia has been reported for many years, it has been only during the past few decades that species within the B. cepacia complex have emerged as significant opportunistic human pathogens. Individuals with cystic fibrosis, the most common inherited genetic disease in Caucasian populations, or chronic granulomatous disease, a primary immunodeficiency, are particularly at risk of life-threatening infection. Despite advances in our understanding of the taxonomy, microbiology, and epidemiology of B. cepacia complex, much remains unknown regarding specific human virulence factors. The broad-spectrum antimicrobial resistance demonstrated by most strains limits current therapy of infection. Recent research efforts are aimed at a better appreciation of the pathogenesis of human infection and the development of novel therapeutic and prophylactic strategies. Key words: Burkholderia cepacia, cystic fibrosis, human infection. Until relatively recently, Burkholderia cepacia had been B. cepacia, possess other factors that remain to be elu- considered a phytopathogenic or saprophytic bacterial cidated that also mediate pathogenicity in this condi- species with little potential for human infection. How- tion (Speert et al., 1994). Fortunately, CGD is a rela- ever, reports of sporadic human infection have ap- tively rare disease, having an average annual incidence peared in the biomedical literature, generally describ- of approximately 1/200,000 live births in the United ing infection in persons with some underlying disease States; this means there are approximately 20 persons or debilitation (Dailey and Benner, 1968; Poe et al., with CGD born each year in the United States.
    [Show full text]
  • Antibiotic Resistance: from the Bench to Patients
    antibiotics Editorial Antibiotic Resistance: From the Bench to Patients Márió Gajdács 1,* and Fernando Albericio 2,3 1 Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Dóm tér 10., 6720 Szeged, Hungary 2 School of Chemistry, University of KwaZulu-Natal, Durban 4001, South Africa 3 Department of Organic Chemistry, University of Barcelona, CIBER-BBN, 08028 Barcelona, Spain * Correspondence: [email protected]; Tel.: +36-62-341-330 Received: 20 August 2019; Accepted: 26 August 2019; Published: 27 August 2019 The discovery and subsequent clinical introduction of antibiotics is one of the most important game-changers in the history of medicine [1]. These drugs have saved millions of lives from infections that would previously have been fatal, and later, they allowed for the introduction of surgical interventions, organ transplantation, care of premature infants, and cancer chemotherapy [2]. Nevertheless, the therapy of bacterial infections is becoming less and less straightforward due to the emergence of multidrug resistance (MDR) in these pathogens [3]. Direct consequences of antibiotic resistance include delays in the onset of the appropriate (effective) antimicrobial therapy, the need to use older, more toxic antibiotics (e.g., colistin) with a disadvantageous side-effect profile, longer hospital stays, and an increasing burden on the healthcare infrastructure; overall, a decrease in the quality-of-life (QoL) and an increase in the mortality rate of the affected patients [4,5]. To highlight the severity of the issue, several international declarations have been published to call governments around the globe to take action on antimicrobial resistance [6–9]. Since the 1980s, pharmaceutical companies have slowly turned away from antimicrobial research and towards the drug therapy of chronic non-communicable diseases [10,11].
    [Show full text]
  • United States Patent ( 10 ) Patent No.: US 10,561,6759 B2 Griffith Et Al
    US010561675B2 United States Patent ( 10 ) Patent No.: US 10,561,6759 B2 Griffith et al. (45 ) Date of Patent : * Feb . 18 , 2020 (54 ) CYCLIC BORONIC ACID ESTER ( 58 ) Field of Classification Search DERIVATIVES AND THERAPEUTIC USES CPC A61K 31/69 ; A61K 31/396 ; A61K 31/40 ; THEREOF A61K 31/419677 (71 ) Applicant: Rempex Pharmaceuticals , Inc. , (Continued ) Lincolnshire , IL (US ) (56 ) References Cited (72 ) Inventors : David C. Griffith , San Marcos, CA (US ) ; Michael N. Dudley , San Diego , U.S. PATENT DOCUMENTS CA (US ) ; Olga Rodny , Mill Valley , CA 4,194,047 A 3/1980 Christensen et al . ( US ) 4,260,543 A 4/1981 Miller ( 73 ) Assignee : REMPEX PHARMACEUTICALS , ( Continued ) INC . , Lincolnshire , IL (US ) FOREIGN PATENT DOCUMENTS ( * ) Notice : Subject to any disclaimer, the term of this EP 1550657 A1 7/2005 patent is extended or adjusted under 35 JP 2003-229277 A 8/2003 U.S.C. 154 ( b ) by 1129 days. (Continued ) This patent is subject to a terminal dis claimer . OTHER PUBLICATIONS Abdel -Magid et al. , “ Reductive Amination ofAldehydes and Ketones ( 21) Appl. No .: 13 /843,579 with Sodium Triacetoxyborohydride: Studies on Direct and Indirect Reductive Amination Procedures ” , J Org Chem . ( 1996 )61 ( 11 ): 3849 ( 22 ) Filed : Mar. 15 , 2013 3862 . (65 ) Prior Publication Data (Continued ) US 2013/0331355 A1 Dec. 12 , 2013 Primary Examiner — Shengjun Wang Related U.S. Application Data (74 ) Attorney, Agent, or Firm — Wilmer Cutler Pickering (60 ) Provisional application No.61 / 656,452 , filed on Jun . Hale and Dorr LLP 6 , 2012 (57 ) ABSTRACT (51 ) Int. Ci. A61K 31/69 ( 2006.01) Method of treating or ameliorating a bacterial infection A61K 31/00 ( 2006.01 ) comprising administering a composition comprising a cyclic (Continued ) boronic acid ester compound in combination with a car ( 52 ) U.S.
    [Show full text]
  • The Fine Structure of Diplococcus Pneumoniae
    THE FINE STRUCTURE OF DIPLOCOCCUS PNEUMONIAE ALEXANDER TOMASZ, Ph.D., JAMES D. JAMIESON, M.D., and ELENA OTTOLENGtII, M.D. From The Rockefeller Institute and the New York University School of Medicine, New York ABSTRACT The fine structure of an unencapsulated strain of Diplococcus pneumoniae is described. A strik- ing feature of thcsc bacteria is an intracytoplasmic membrane system which appears to be an extension of septa of dividing bactcria. The possible function of these structures and their relationship to the plasma membrane and other types of intracytoplasmic membranes found in pncumococcus is discussed. INTRODUCTION Our main interest in the fine structure of Diplo- walls. Throughout this paper, such preparations will coccus pneumoniae stems from the fact that these be referred to as "spheroplasts." bacteria readily undergo genetic transformation. The bacteria were fixed and stained according to the method of Ryter and Kellenberger (4), embedded Prior to undertaking electron microscope studies in cross-linked methacrylate, and sectioned with a on this process, the fine structure of pneumococcal Porter-Blum mlcrotome using a diamond knife. The cells in thin sections was examined. During the sections were stained with lead according to the preliminary stage of these studies on a transform- method of Karnovsky (5) (method B) and were able strain, we observed some unique membranous examined in the RCA electron microscopes models structures which, to the best of our knowledge, 2B, 3F, or in the Siemens Elmiskop I. have not previously been described in bacteria. RESULTS MATERIALS AND METHODS The nuclear region of pneumococcus resembles that Unencapsulated strains of Diplocoecus pneumoniae R6, of other bacteria prepared by the method of R1, and some nutritional mutants derived from R6 Ryter and Kellenberger (4).
    [Show full text]
  • Pathological and Therapeutic Approach to Endotoxin-Secreting Bacteria Involved in Periodontal Disease
    toxins Review Pathological and Therapeutic Approach to Endotoxin-Secreting Bacteria Involved in Periodontal Disease Rosalia Marcano 1, M. Ángeles Rojo 2 , Damián Cordoba-Diaz 3 and Manuel Garrosa 1,* 1 Department of Cell Biology, Histology and Pharmacology, Faculty of Medicine and INCYL, University of Valladolid, 47005 Valladolid, Spain; [email protected] 2 Area of Experimental Sciences, Miguel de Cervantes European University, 47012 Valladolid, Spain; [email protected] 3 Area of Pharmaceutics and Food Technology, Faculty of Pharmacy, and IUFI, Complutense University of Madrid, 28040 Madrid, Spain; [email protected] * Correspondence: [email protected] Abstract: It is widely recognized that periodontal disease is an inflammatory entity of infectious origin, in which the immune activation of the host leads to the destruction of the supporting tissues of the tooth. Periodontal pathogenic bacteria like Porphyromonas gingivalis, that belongs to the complex net of oral microflora, exhibits a toxicogenic potential by releasing endotoxins, which are the lipopolysaccharide component (LPS) available in the outer cell wall of Gram-negative bacteria. Endotoxins are released into the tissues causing damage after the cell is lysed. There are three well-defined regions in the LPS: one of them, the lipid A, has a lipidic nature, and the other two, the Core and the O-antigen, have a glycosidic nature, all of them with independent and synergistic functions. Lipid A is the “bioactive center” of LPS, responsible for its toxicity, and shows great variability along bacteria. In general, endotoxins have specific receptors at the cells, causing a wide immunoinflammatory response by inducing the release of pro-inflammatory cytokines and the production of matrix metalloproteinases.
    [Show full text]
  • AMR Surveillance in Pharma: a Case-Study for Data Sharingauthor by Professor Barry Cookson
    AMR Open Data Initiative AMR Surveillance in Pharma: a case-study for data sharingauthor by Professor Barry Cookson External Consultant to Project eLibrary • Division of Infection and Immunity, Univ. College London ESCMID• Dept. of Microbiology, © St Thomas’ Hospital Background of “90 day Project” Addressed some recommendations of the first Wellcome funded multi-disciplinary workshop (included Pharma Academia & Public Health invitees: 27thauthor July 2017 (post the Davos Declaration): by 1) Review the landscape of existing Pharma AMR programmes, their protocols,eLibrary data standards and sets 2) Develop a "portal" (register/platform) to access currently available AMR Surveillance data ESCMID Important ©to emphasise that this is a COLLABORATION between Pharma and others Overview of Questionnaire Content • General information - including name,author years active, countries, antimicrobials, microorganisms.by • Methodology - including accreditation, methodology for; surveillance, isolate collection, organism identification, breakpointseLibrary used, • Dataset - including data storage methodology, management and how accessed. ESCMID © 13 Company Responses author 7 by 3 3 eLibrary ESCMID © Structure of register Companies can have different ways of referring to their activities: We had to choose a consistent framework. author Companies Companyby 1 Programmes Programme A Programme B eLibrary Antimicrobials 1 2 3 4 5 company’s product comparator company’s product antimicrobials Programmes canESCMID contain multiple studies (e.g. Pfizer has© single
    [Show full text]
  • Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020
    First independent framework for assessing pharmaceutical company action Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report.1 FUNDERS The Antimicrobial Resistance Benchmark research programme is made possible with financial support from UK AID and the Dutch Ministry of Health, Welfare and Sport. Expert Review Committee Research Team Reviewers Hans Hogerzeil - Chair Gabrielle Breugelmans Christine Årdal Gregory Frank Fatema Rafiqi Karen Gallant Nina Grundmann Adrián Alonso Ruiz Hans Hogerzeil Magdalena Kettis Ruth Baron Hitesh Hurkchand Joakim Larsson Dulce Calçada Joakim Larsson Marc Mendelson Moska Hellamand Marc Mendelson Margareth Ndomondo-Sigonda Kevin Outterson Katarina Nedog Sarah Paulin (Observer) Editorial Team Andrew Singer Anna Massey Deirdre Cogan ACCESS TO MEDICINE FOUNDATION Rachel Jones The Access to Medicine Foundation is an independent Emma Ross non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income Additional contributors countries by stimulating and guiding the pharmaceutical Thomas Collin-Lefebvre industry to play a greater role in improving access to Alex Kong medicine. Nestor Papanikolaou Address Contact Naritaweg 227-A For more information about this publication, please contact 1043 CB, Amsterdam Jayasree K. Iyer, Executive Director The Netherlands [email protected] +31 (0) 20 215 35 35 www.amrbenchmark.org 1 This acknowledgement is not intended to imply that the individuals and institutions referred to above endorse About the cover: Young woman from the Antimicrobial Resistance Benchmark methodology, Brazil, where 40%-60% of infections are analyses or results.
    [Show full text]